Innate immunity in hypertension topical collection on hypertension and metabolic syndrome

Current Hypertension Reports

Volumn 16, Issue 2, 2014, Pages

  Mian, Muhammad Oneeb Rehman ^a   Paradis, Pierre ^a   Schiffrin, Ernesto L ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Blood pressure; DAMPs; Inflammation; Innate immunity; Target organ damage; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; DAMAGE ASSOCIATED MOLECULAR PATTERN; EFFECTOR CELL; HUMAN; HYPERTENSION; INNATE IMMUNITY; MACROPHAGE FUNCTION; MOLECULAR RECOGNITION; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PARASYMPATHETIC TONE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; T LYMPHOCYTE ACTIVATION; ANIMAL; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; REVIEW; T LYMPHOCYTE;

ANIMALS; HUMANS; HYPERTENSION; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGES; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84893743675     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0413-9     Document Type: Article

References (68)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
2. Leibowitz A, Schiffrin EL. Immune mechanisms in hypertension. Curr Hypertens Rep. 2011;13:465-72.
3. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension. 2012;59:367-74.
4. Tian N, Moore RS, Braddy S, et al. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol. 2007;293:H3388-95.
5. Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29:543-8. This review discusses the role of T effector and regulatory lymphocytes in blood pressure regulation.
6. Barhoumi T, Kasal DA, Li MW, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469-76.
7. Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59:324-30.
8. Franco M, Martinez F, Quiroz Y, et al. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol. 2007;293:R251-6.
9. De Ciuceis C, Amiri F, Brassard P, et al. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol. 2005;25:2106-13.
10. Ko EA, Amiri F, Pandey NR, et al. Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am J Physiol Heart Circ Physiol. 2007;292:H1789-95.
11. Leibovitz E, Ebrahimian T, Paradis P, et al. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009;27:2192-200.
12. Javeshghani D, Barhoumi T, Idris-Khodja N, et al. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension. 2013;62:112-7. This study shows that macrophages play a role in endothelin-1-induced vascular injury.
13. iDTR mice).
14. Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci. 2014;126:267-74. Review of the role of immune mechanisms in vascular injury in hypertension with an in-depth description of the mechanisms of action of T regulatory lymphocytes.
15. Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res. 2004;94:1203-10.
16. Elmarakby AA, Quigley JE, Olearczyk JJ, et al. Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension. 2007;50:1069-76.
17. Liao TD, Yang XP, Liu YH, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 2008;52:256-63.
18. Kossmann S, Schwenk M, Hausding M, et al. Angiotensin II-induced vascular dysfunction depends on interferon-gamma-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arterioscler Thromb Vasc Biol. 2013;33:1313-9. This study demonstrates that NK cells, in cooperation with monocytes, produce IFN-γ, which is important for angiotensin II-induced vascular damage.
19. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-81.
20. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004;44:248-52.
21. Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537-43.
22. Kriska T, Cepura C, Magier D, et al. Mice lacking macrophage 12/15-lipoxygenase are resistant to experimental hypertension. Am J Physiol Heart Circ Physiol. 2012;302:H2428-38.
23. Machnik A, Neuhofer W, Jantsch J, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009;15:545-52. In this and the following study (ref. [24]••), the authors demonstrated a role for skin macrophages in the regulation of salt and water retention, and therefore blood pressure regulation.
24. Machnik A, Dahlmann A, Kopp C, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension. 2010;55:755-61. See above, ref. [23]•.
25. Yamamoto S, Yancey PG, Zuo Y, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:2856-64.
26. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Investig. 2010;120:3350-64.
27. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity. 2011;35:323-35.
28. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010;10:236-47.
29. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336-47.
30. Vinh A, Chen W, Blinder Y, et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122:2529-37. The authors demonstrated that costimulation of T cells via B7 is critical for the development of hypertension in response to angiotensin II.
31. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-40.
32. Taherzadeh Z, VanBavel E, de Vos J, et al. Strain-dependent susceptibility for hypertension in mice resides in the natural killer gene complex. Am J Physiol Heart Circ Physiol. 2010;298:H1273-82.
33. de Vries MR, Seghers L, van Bergen J, et al. C57BL/6 NK cell gene complex is crucially involved in vascular remodeling. J Mol Cell Cardiol. 2013;64C:51-8.
34. Jin C, Henao-Mejia J, Flavell RA. Innate immune receptors: key regulators of metabolic disease progression. Cell Metab. 2013;17:873-82.
35. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
36. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007;4:444-54.
37. Bomfim GF, Dos Santos RA, Oliveira MA, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci. 2012;122:535-43.
38. Wallin RP, Lundqvist A, More SH, et al. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 2002;23:130-5.
39. Pockley AG, Wu R, Lemne C, et al. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension. 2000;36:303-7.
40. Pons H, Ferrebuz A, Quiroz Y, et al. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am J Physiol Ren Physiol. 2013;304:F289-99.
41. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA: J Am Med Assoc. 2008;300:924-32.
42. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-21.
43. Davey Smith G, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25:1051-6.
44. Miller YI, Chang MK, Binder CJ, et al. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003;14:437-45.
45. Taguchi A, Sanada M, Suei Y, et al. Tooth loss is associated with an increased risk of hypertension in postmenopausal women. Hypertension. 2004;43:1297-300.
46. Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356:911-20.
47. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59:755-62. This is a brief but good review on autonomic neural regulation of the immune system in hypertension and cardiovascular disease with an emphasis on the anti-inflammatory role of the parasympathetic system.
48. Elenkov IJ, Wilder RL, Chrousos GP, et al. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595-638.
49. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-46.
50. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
51. Grebe KM, Takeda K, Hickman HD, et al. Cutting edge: sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis. J Immunol. 2010;184:540-4.
52. Grisanti LA, Woster AP, Dahlman J, et al. Alpha1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. J Pharmacol Exp Ther. 2011;338:648-57.
53. Harwani SC, Chapleau MW, Legge KL, et al. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res. 2012;111:1190-7.
54. Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in hypertension. Front Physiol. 2012;3:128. This review comprehensively discusses the recent data on the roles of innate and adaptive immunity in hypertension.
55. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-7.
56. Pietrowski E, Bender B, Huppert J, et al. Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H- oxidase derived reactive oxygen species. J Vasc Res. 2011;48:52-8.
57. Lee DL, Leite R, Fleming C, et al. Hypertensive response to acute stress is attenuated in interleukin-6 knockout mice. Hypertension. 2004;44:259-63.
58. Brands MW, Banes-Berceli AK, Inscho EW, et al. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension. 2010;56:879-84.
59. Zhang W, Wang W, Yu H, et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension. 2012;59:136-44.
60. Shao J, Nangaku M, Miyata T, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension. 2003;42:31-8.
61. Viel EC, Lemarie CA, Benkirane K, et al. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol. 2010;298:H938-44.
62. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523-32.
63. Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993-9.
64. Sales ML, Schreiber R, Ferreira-Sae MC, et al. The functional Toll-like receptor 4 Asp299Gly polymorphism is associated with lower left ventricular mass in hypertensive women. Clin Chim Acta Int J Clin Chem. 2010;411:744-8.
65. Sales ML, Schreiber R, Ferreira-Sae MC, et al. Toll-like receptor 6 Ser249Pro polymorphism is associated with lower left ventricular wall thickness and inflammatory response in hypertensive women. Am J Hypertens. 2010;23:649-54.
66. Marketou ME, Kontaraki JE, Zacharis EA, et al. TLR2 and TLR4 gene expression in peripheral monocytes in nondiabetic hypertensive patients: the effect of intensive blood pressure-lowering. J Clin Hypertens. 2012;14:330-5.
67. Marketou ME, Kontaraki JE, Tsakountakis NA, et al. Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am J Cardiol. 2011;107:59-63.
68. Imakiire T, Kikuchi Y, Yamada M, et al. Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. Hypertens Res: Off J Japan Soc Hypertens. 2007;30:635-42.